在心力衰竭住院患者出院前优化药物使用情况
Joseph J Cuthbert1,2, Oliver I Brown1,2, Pierpaolo Pellicori3
1Clinical Sciences Centre, Hull York Medical School, University of Hull, Kingston upon Hull, East Riding of Yorkshire, UK.
ESC heart failure
|January 17, 2024
概括
大多数心力衰竭患者在出院后有资格获得延长寿命的药物. 住院提供了一个错过的机会,以优化心力衰竭的治疗,减少喷射率 (HeFREF).
科学领域:
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
- 内部医学 内部医学
背景情况:
- 减少喷射分数 (HeFREF) 的心力衰竭影响了许多患者.
- 三重疗法 (ACE-I/ARB,BB,MRA) 是标准的排出治疗方法.
- 最佳剂量和适用于新疗法的资格往往不够理想.
研究的目的:
- 为了确定HeFREF患者在出院前获得最佳剂量的比例.
- 评估适用于萨库比特里尔-瓦尔萨坦和SGLT2抑制剂的资格.
- 为了确定启动或升级指南导向医疗治疗的障碍.
主要方法:
- 在2012-2017年期间出院的455名HeFREF患者的回顾性分析.
- 根据临床试验标准,适用于萨库比特里尔-瓦尔萨坦和SGLT2抑制剂的资格.
- 评估药物使用,功能,心率和缩血压.
主要成果:
- 83%的人在放药时接受了ACE-I/ARB,85%的BB,63%的MRA.
- >60%符合萨库比特里尔-瓦尔萨坦的条件; >70%的SGLT2抑制剂.
- 低缩血压 (≤105 mmHg) 是不启动/升位治疗的一个关键原因.
结论:
- 住院是优化HeFREF治疗的关键窗口.
- 许多患者有资格接受先进疗法,如萨库比特里尔-瓦尔萨坦和SGLT2抑制剂.
- 解决低血压等障碍可以改善指导方针导向的医疗治疗启动.
相关概念视频
01:22Heart Failure Drugs: Diuretics
384
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
384
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
432
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
432
01:22Heart Failure Drugs: β-Blockers
341
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
341
01:26Heart Failure Drugs: Inotropic Agents
591
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
591
01:11Renal Failure: Dose Adjustments
92
In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
92
01:17Pathophysiology of Heart Failure
1.6K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.6K